SCHEMBL14909142

SCHEMBL14909142

CC(C)(C)N(C(=O)O)C(CN)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 3/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 2/20 0.40
CYP3A4 P08684 2/20 0.40
LMNA P02545 2/20 0.40
RAB9A P51151 1/20 0.40
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
CHRM2 P08172 1/20 0.38
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KCNA5 P22460 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14909140 1.00 CYP2C19 (0.47) CYP2C19CYP1A2ALDH1A1POLBKDM4E
SCHEMBL14909537 0.79 SLC6A2 (0.42) KDM4ESLC6A2SLC6A4MEN1GAA
SCHEMBL9716115 0.79 SLC6A2 (0.42) KDM4ESLC6A2SLC6A4MEN1GAA
SCHEMBL1231239 0.79 SLC6A2 (0.42) KDM4ESLC6A2SLC6A4MEN1GAA
SCHEMBL14908841 0.79 KMT2A (0.44) CYP2C19CYP1A2ALDH1A1KDM4ERAB9A
SCHEMBL14910023 0.79 KMT2A (0.44) CYP2C19CYP1A2ALDH1A1KDM4ERAB9A
SCHEMBL14908840 0.79 KMT2A (0.44) CYP2C19CYP1A2ALDH1A1KDM4ERAB9A
SCHEMBL28829789 0.76 CYP2C19 (0.42) CYP2C19CYP1A2ALDH1A1POLBKDM4E
SCHEMBL14910818 0.74 SMN1; SMN2 (0.40) CYP2C19ALDH1A1TSHRCYP3A4LMNA
SCHEMBL14910817 0.74 SMN1; SMN2 (0.40) CYP2C19ALDH1A1TSHRCYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK CYP2C19 3799/4885CYP1A2 4413/4885ALDH1A1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.